The ASB3 antibody targets the Ankyrin Repeat and SOCS Box Protein 3 (ASB3), a member of the ASB family involved in ubiquitination-mediated protein degradation. ASB proteins typically function as substrate-recognition components of E3 ubiquitin ligase complexes via their SOCS box domain, facilitating proteasomal degradation of specific targets. ASB3 contains ankyrin repeats, which mediate protein-protein interactions, and a SOCS box that binds Elongin B/C to recruit E3 ligase machinery.
ASB3 has been implicated in regulating cellular processes such as signal transduction, apoptosis, and cell proliferation. Studies suggest its role in modulating pathways like NF-κB and TGF-β, influencing inflammation and cancer progression. Notably, ASB3 may act as a tumor suppressor in certain cancers by targeting oncoproteins for degradation. For example, it has been shown to ubiquitinate and degrade IRS-1 (Insulin Receptor Substrate 1), impacting insulin signaling and tumor growth.
ASB3 antibodies are essential tools for detecting ASB3 expression in tissues or cell lines, enabling research into its biological functions and disease associations. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of ASB3 has been observed in malignancies such as colorectal and breast cancers, highlighting its potential diagnostic or therapeutic relevance. However, its precise mechanisms and full range of substrates remain under investigation, necessitating further studies to clarify its pathophysiological roles.